Divi's Lab shares mount 8.12 percent
Bangalore: Divi's Lab (DIVISLAB) ended the trading as one of the top gainers of the day with a gain of 
39.90 (8.12 percent). The market of Divi's opened its account today with a gain of 1.55 points to its previous close of 491.45. During the whole day, the stock has touched a high of 537 and a low of 489. The stock has touched a 52-week high of 793 and a low of 382.53. The P/E ratio of the stock is 21.04. With 304,793 units of shares, 'Reliance Vision Fund - Retail Plan' holds the highest number of shares in Divi's Lab. The 52 week stock price chart is on the left.
Divi's Lab is an India based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. The major portion of the company's turnover is on account of export of its products to European and American countries. The company's main manufacturing and research and development facilities are located in Andhra Pradesh. The company has developed multistep total synthesis of important carotenoids like betacarotene, lycopene, astaxanthin and canthaxanthin. The company's subsidiaries include Divis Laboratories (U.S.) and Divis Laboratories (Europe) AG. In the financial year (FY) 2008-09, the company reported 19.83 percent increase in annual profit. The profit stood at 417 crore. Revenues, on the other hand increased by 14.23 percent to 1,180 crore.
Out of 10 stock analysts currently following Divi's Lab, consensus recommendation is hold, while three recommend to buy, two rate it as underperform and one recommend to sell.
Other pharmaceuticals companies have also ended the trading on positive zone. Orchid Chemicals went up by 3.67 percent, Nectar Life Sciences gained by 1.15 percent and Smruthi Organics up by 4.91 percent.
39.90 (8.12 percent). The market of Divi's opened its account today with a gain of 1.55 points to its previous close of 491.45. During the whole day, the stock has touched a high of 537 and a low of 489. The stock has touched a 52-week high of 793 and a low of 382.53. The P/E ratio of the stock is 21.04. With 304,793 units of shares, 'Reliance Vision Fund - Retail Plan' holds the highest number of shares in Divi's Lab. The 52 week stock price chart is on the left.
Divi's Lab is an India based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. The major portion of the company's turnover is on account of export of its products to European and American countries. The company's main manufacturing and research and development facilities are located in Andhra Pradesh. The company has developed multistep total synthesis of important carotenoids like betacarotene, lycopene, astaxanthin and canthaxanthin. The company's subsidiaries include Divis Laboratories (U.S.) and Divis Laboratories (Europe) AG. In the financial year (FY) 2008-09, the company reported 19.83 percent increase in annual profit. The profit stood at 417 crore. Revenues, on the other hand increased by 14.23 percent to 1,180 crore.
Out of 10 stock analysts currently following Divi's Lab, consensus recommendation is hold, while three recommend to buy, two rate it as underperform and one recommend to sell.
Other pharmaceuticals companies have also ended the trading on positive zone. Orchid Chemicals went up by 3.67 percent, Nectar Life Sciences gained by 1.15 percent and Smruthi Organics up by 4.91 percent.